[Form 4] Alaunos Therapeutics, Inc. Insider Trading Activity

Rhea-AI Filing Summary

Ferdinand Groenewald, identified as Vice President of Finance at Alaunos Therapeutics, Inc. (TCRT), reported transactions dated 08/18/2025. He acquired 10,775 shares of common stock and was granted an employee stock option for 4,000 shares with an exercise price of $2.32 and an expiration date of 08/17/2035. The option vests one-sixteenth of the underlying shares in equal quarterly installments beginning 11/18/2025, subject to continued service.

The Form 4 shows the shares and options are held directly after the transactions. The filing is signed by Mr. Groenewald on 08/20/2025. No additional compensation details or company valuation metrics are provided in this filing.

Positive

• Officer increased direct ownership by acquiring 10,775 common shares, aligning management interests with shareholders
• Received an employee stock option for 4,000 shares with clear vesting schedule and a defined exercise price of $2.32
• Vesting schedule disclosed (one-sixteenth quarterly installments beginning 11/18/2025), providing transparency on future potential dilution

Negative

• None.

Insights

Financial Analyst

TL;DR: Officer purchased shares and received options, indicating personal ownership increase but no material company metrics disclosed.

The filing documents a direct acquisition of 10,775 common shares and a 4,000-share employee option exercisable at $2.32 through 08/17/2035 with scheduled quarterly vesting beginning 11/18/2025. From a financial-analyst perspective, these transactions show management ownership alignment with shareholders; however, the filing contains no revenue, valuation, or relative position data to assess materiality.

Corporate Governance Expert

TL;DR: Insider transaction reflects typical equity compensation and direct ownership disclosure; no governance issues stated.

The Form 4 properly discloses the reporting person's role as Vice President of Finance and details of the equity grant and stock acquisition. Vesting is time-based with one-sixteenth quarterly installments after 08/18/2025. The disclosure appears compliant with Section 16 reporting requirements; the filing does not indicate any transfers, pledges, or related-party arrangements beyond the direct holdings reported.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Groenewald Ferdinand

(Last) (First) (Middle)

C/O ALAUNOS THERAPEUTICS, INC.

501 E. LAS OLAS BLVD., SUITE 300

(Street)

FORT LAUDERDALE FL 33301

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Alaunos Therapeutics, Inc. [ TCRT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Vice President of Finance

3. Date of Earliest Transaction (Month/Day/Year)
08/18/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/18/2025	08/18/2025	A		10,775	A	$0.00	10,775	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Stock Option (right to buy)	$2.32	08/18/2025		A		4,000		(1)	08/17/2035	Common Stock	4,000	$0.00	4,000	D

Explanation of Responses:

1. One-sixteenth of the shares underlying the option vest in equal quarterly installments measured from August 18, 2025, with the first vesting occurring on November 18, 2025 subject to the Reporting Person's continued service through each vesting date.

	/s/ Ferdinand Groenewald	08/20/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

Who filed the Form 4 for TCRT and what is their role?

Ferdinand Groenewald, Vice President of Finance at Alaunos Therapeutics, Inc., filed the Form 4.

What securities did the reporting person acquire on 08/18/2025?

He acquired 10,775 shares of common stock and was granted an employee stock option for 4,000 shares.

What are the key terms of the stock option reported in the Form 4?

The option has an exercise price of $2.32, is exercisable per the schedule, and expires on 08/17/2035.

When does the option vest according to the filing?

Vesting is one-sixteenth of the shares in equal quarterly installments beginning 11/18/2025, contingent on continued service.

How are the reported holdings held (direct or indirect)?

Both the acquired common shares and the option underlying shares are reported as held directly.